Potential uses of interleukin 2 in cancer therapy (Q39724074)

14 September 2017

title

Potential uses of interleukin 2 in cancer therapy (English)

1 reference

14 September 2017

Cheever MA

1

1 reference

14 September 2017

Thompson JA

series ordinal

2

1 reference

14 September 2017

Peace DJ

series ordinal

3

1 reference

14 September 2017

Greenberg PD

series ordinal

4

1 reference

14 September 2017

publication date

1 September 1986

1 reference

14 September 2017

1 reference

14 September 2017

volume

172

1 reference

14 September 2017

issue

3-5

1 reference

14 September 2017

page(s)

365-382

1 reference

T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Studies on chemically induced rat tumors. II. Partial protection against syngeneic lethal tumors by cloned syngeneic cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Genetic control of the immune response to Thy-1 antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

In vivo localization of cloned IL-2-dependent T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980118-8

7 January 2021

10.1016/S0171-2985(86)80118-8

Identifiers

DOI

0 references

1 reference